Miner P B
Oklahoma Foundation for Digestive Research, Oklahoma City 73104, USA.
Am J Gastroenterol. 1997 Dec;92(12 Suppl):1S-4S.
The management of relapse of inflammatory bowel disease (IBD) remains a clinical challenge and a relatively neglected area of current research. Many factors contribute to relapse, and the proper identification of the cause of each case may influence optimal management. Often, relapse is related to the failure of maintenance therapy. Mesalamine sensitivity is difficult to recognize and should be considered when increased doses are associated with the worsening of symptoms. An increase in eosinophil activity could explain seasonal relapses of IBD as a result of exposure to allergens, but other eosinophil activation pathways also will influence the course of IBD. Infection, either enteric or systemic, may trigger a relapse by activating the gastrointestinal mucosal immune system. Nonsteroidal anti-inflammatory drug use is a well-recognized cause of exacerbation of disease. Smoking status is emerging as a complex factor in IBD, and a change in smoking status may influence the course of IBD.
炎症性肠病(IBD)复发的管理仍然是一项临床挑战,也是当前研究中一个相对被忽视的领域。许多因素导致复发,正确识别每个病例的病因可能会影响最佳管理。通常,复发与维持治疗失败有关。美沙拉嗪敏感性难以识别,当增加剂量与症状恶化相关时应予以考虑。嗜酸性粒细胞活性增加可能解释了因接触过敏原导致的IBD季节性复发,但其他嗜酸性粒细胞激活途径也会影响IBD的病程。肠道或全身性感染可能通过激活胃肠道黏膜免疫系统引发复发。使用非甾体类抗炎药是公认的疾病加重原因。吸烟状况正在成为IBD中的一个复杂因素,吸烟状况的改变可能会影响IBD的病程。